Mavacamten HCM denied as duplicate or overlapping therapy by Aetna?

Aetna's specific coverage criteria for mavacamten hcm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Mavacamten as Duplicate Therapy — and Why You Can Appeal

Mavacamten is a first-in-class cardiac myosin inhibitor approved specifically for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A duplicate-therapy denial signals that Aetna's system has flagged another drug on your profile — typically a traditional heart-rate-lowering agent such as a beta-blocker or non-dihydropyridine calcium channel blocker — and treated mavacamten as redundant. This classification fundamentally misunderstands the pharmacology: mavacamten targets the underlying myosin-actin cross-bridge mechanism of oHCM and is not pharmacologically interchangeable with rate-controlling agents. The denial is clinically incorrect and is very commonly reversed on appeal.

## Why This Denial Is Appealable

Duplicate-therapy edits are usually automated, rules-based denials that do not account for a drug's novel mechanism of action. Because mavacamten is the only approved cardiac myosin inhibitor and acts through a pathway entirely distinct from beta-blockers, calcium channel blockers, or disopyramide, it cannot be clinically duplicative of any currently marketed medication. Your prescriber's letter explaining this distinction is typically the central piece of evidence needed.

## Federal Appeal Framework

• Internal appeal: File within the timeframe in your denial letter. Request the specific clinical criteria and drug-interaction or duplicate-therapy policy Aetna applied.
• External review (ACA §2719): If the internal appeal fails, most non-grandfathered plan members may seek independent external review within approximately four months of final denial.
• ERISA §503: Employer-plan members are entitled to a full-and-fair review.
• Expedited review: Request if symptom progression creates urgency; response required within 72 hours.

## Documentation to Gather

• Diagnosis confirmation: Specialist records confirming symptomatic oHCM, imaging, and clinical assessment.
• Current medication list with rationale: Documentation of all current cardiac medications, their indications, and why each serves a distinct clinical purpose.
• Prescriber medical-necessity letter: A letter from the cardiologist or HCM specialist explaining mavacamten's unique mechanism, why it is not duplicative of any current therapy, and how the combination aligns with the FDA-approved label and applicable cardiology society guidelines.
• FDA label reference: The prescriber letter should reference the FDA-approved indication and mechanism of action directly.

## Criteria-Mapping Structure

Request Aetna's duplicate-therapy clinical policy in writing. Then address each stated criterion:

| Policy Requirement | Chart / Documentation Response | |---|---| | Proposed drug is not therapeutically equivalent to a current drug | [Prescriber letter citing distinct mechanism — cardiac myosin inhibition] | | Diagnosis consistent with FDA-approved indication | [ICD code, specialist note confirming symptomatic oHCM] | | Clinical necessity for combination not met by existing therapy | [Documentation of persistent symptoms on current regimen] |

A concise pharmacology explanation from the treating cardiologist, paired with the FDA label, typically resolves this denial at the first internal appeal level.